Page 4 - Crown Bioscience News Today

/PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms offering....

/PRNewswire/ -- The "Global Cardiovascular Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms...

/PRNewswire/ -- After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics...

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH

In 2021, the global Oncology-based In-vivo CRO Market was estimated to be worth around $1 billion. With a projected CAGR of 10.9% over the next ten years, the market is expected to be worth nearly US$ 2.9 billion by the end of 2033. By 2033, the absolute dollar opportunity in the Oncology-based In-vivo CRO Market is...

JSR Life Sciences, LLC ("JSR") today announced that Similis Bio ("Similis"), its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH.

Acquisition expands global service offering to include access and analysis of unique clinical biospecimens Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences

Crown Bioscience, a global contract research organization (CRO), and JSR Life Sciences company, announced today their newly published study in PLOS ONE, a journal of the Public Library of Science (PLOS)

Dublin, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The "Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung,...